ScreenerHero
FAGRFagron NV
EBR · BE · Healthcare · Drug Manufacturers - Specialty & Generic · fagron.com
22.40EUR+0.22%Mkt Cap: 1.78B $P/E: 17.88

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. It operates through three segments: Essentials, Brands, and Compoundi…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.24BUSDP/E 23.7
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.41BUSDP/E 20.1
ZOE
Zoetis Inc.
$29.37BUSDP/E 12.4
UTHR
United Therapeutics Corporation
$22.70BUSDP/E 19.0
VTRS
Viatris, Inc.
$18.66BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.39BUSDP/E 118.0
NBIX
Neurocrine Biosciences, Inc.
$15.81BUSDP/E 22.8
IPN
Ipsen S.A.
$14.67BUSDP/E 26.5
ELAN
Elanco Animal Health Incorporat
$12.24BUSD
KRK
Krka, d. d.
$8.57BUSDP/E 18.8
HIMS
Hims & Hers Health, Inc.
$7.25BUSD
LQDA
Liquidia Corporation
$6.74BUSDP/E 53.8
LNTH
Lantheus Holdings Inc
$6.56BUSDP/E 24.0
AMRX
Amneal Pharmaceuticals, Inc.
$6.23BUSDP/E 37.3
INDV
Indivior PLC Ordinary Shares
$4.61BUSDP/E 14.0
HIK
Hikma Pharmaceuticals PLC
$4.32BUSDP/E 12.5
AMLX
Amylyx Pharmaceuticals Inc. Common Stock
$4.30BUSD
SFZN
Siegfried Holding AG
$3.91BUSDP/E 20.4
ROVI
Laboratorios Farmaceuticos Rovi, S.A.
$3.34BUSDP/E 16.6
SUPN
Supernus Pharmaceuticals, Inc.
$2.82BUSD

Key Statistics

Company
Market Cap1.78B $
Enterprise Value2.34B $
Revenue (TTM)1.12B $
Gross Profit469.57M $
Net Income (TTM)98.93M $
Revenue/Share15.26 USD
Last Price22.40 EUR
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees4.9K
CountryBE
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINBE0003874915
Valuation
P/E (Trailing)17.88
P/E (Forward)13.59
PEG15.84
EV/EBITDA12.32
EV/Revenue2.09
P/S1.59
P/B2.76
EPS (TTM)1.25
EPS (Forward)1.64
52W Range
19.2452% of range25.30
52W High25.30 EUR
52W Low19.24 EUR
Profitability
Gross Margin45.37%
Oper. Margin13.72%
EBITDA Margin16.98%
Profit Margin9.56%
ROE16.50%
ROA7.32%
Growth
Revenue Growth16.00%
Earnings Growth1.60%
Cash Flow & Leverage
Operating CF168.76M $
CapEx (TTM)33.27M $
FCF Margin6.54%
FCF Yield4.10%
Net Debt550.47M $
Net Debt/EBITDA2.90
Balance Sheet
Debt/Equity0.85
Current Ratio1.77
Quick Ratio1.02
Book Value/Sh8.107 EUR
Cash/Share1.789 EUR
Dividends
Fwd Div Rate0.4000 EUR
Trail. Div Rate0.4000 EUR
Div. Yield1.79%
5Y Avg Yield1.48%
Payout Ratio32.00%
Ex-Div DateMay 18, 2026
Pay Date—
Analyst Consensus
Rating—
Target (Mean)28.75 EUR
Upside (mean)+28.3%
Target Range27.50 EUR – 31.00 EUR
€27.50+28.3% to mean€31.00
# Analysts6
Ownership
Shares Out.73.35M
Float65.85M
Insiders0.30%
Institutions71.70%
Technical
SMA 5023.52 (-4.8%)
SMA 20022.67 (-1.2%)
Beta0.38
S&P 52W Chg18.16%
Avg Vol (30d)83.33K
Avg Vol (10d)75.95K
Technical Indicators
RSI (14)38.5
MACD-0.3597
MACD Signal-0.3671
MACD Hist.+0.0073
BB Upper23.67 EUR
BB Middle22.73 EUR
BB Lower21.80 EUR
BB Width8.22%
ATR (14)0.4025 EUR
Vol Ratio (20d)0.73x